Skip to main content
Clinical Trials/NCT06735898
NCT06735898
Recruiting
Not Applicable

Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN® Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome

POLYSAN Scientific & Technological Pharmaceutical Company1 site in 1 country90 target enrollmentMarch 1, 2024
ConditionsIschemic Stroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ischemic Stroke
Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Enrollment
90
Locations
1
Primary Endpoint
Dynamics of rehabilitation routing status score
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Post intensive care syndrome (PIC syndrome) is an important problem in modern intensive care strategy. Understanding the mechanisms of PIC syndrome helps prevent it in patients with respiratory, neuromuscular transmission, and cognitive impairments that require prolonged support of vital functions. Significant role in the formation and severity of PIC syndrome is played by the severity of the systemic inflammatory response, which is an individual reaction of the body, and this determines the degree of neurological and psychological deficits. Chronic diseases such as diabetes mellitus, especially in the context of metabolic syndrome, worsen the course of PIC syndrome and delays recovery. Early initiation of rehabilitation measures in the intensive care unit and subsequent expansion of the individual rehabilitation program contributes to the rapid and successful recovery of not only vital functions, but also cognitive, motor and emotional disorders. This shortens the hospital stay of patient and improves their quality of life after discharge.

Registry
clinicaltrials.gov
Start Date
March 1, 2024
End Date
May 1, 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Men and women over 18 years of age and older;
  • Stay in the ITU and (or) intensive care unit for at least 3 days;
  • Diagnosed "post intensive care" syndrome (PIC syndrome) with moderate-to-severe severity \>3\<6 points
  • Diagnosed modalities "critical illness polyneuropathy, respiratory neuropathy, dysphagia" of the domain "Neuromuscular complications" of PIC syndrome at 2-3 stages of the rehabilitation route at any value of PICS severity index
  • Diagnosed modalities "decreased gravitational gradient, decreased exercise tolerance" in the domain "Vegetative-metabolic complications" at 2-3 stages of the rehabilitation route at any value of PICS severity index

Exclusion Criteria

  • Premorbid level of vital activity when assessed on the rehabilitation routing scale 4-5 points;
  • Hematocrit ≤30%;
  • Hemoglobin level ≤80 g/L;
  • Acute cardiac failure;
  • Acute respiratory failure;
  • Acute renal failure;
  • Acute liver cell failure;
  • Use of drugs from "metabolic agents" pharmacotherapeutic group at the time of inclusion in the study
  • Life expectancy of 6 months or less or presence of incurable diseases in decompensation stage

Outcomes

Primary Outcomes

Dynamics of rehabilitation routing status score

Time Frame: day 12, day 30, day 60, day 90

Dynamics of rehabilitation routing status score from the start of the study (Visit 1) to Visit 3, Visit 4, Visit 5 and Visit 6 measured in both groups

Dynamics of Barthel status score

Time Frame: day 12, day 30, day 60, day 90

Dynamics of Barthel status score from the start of the study (Visit 1) to Visit 3, Visit 4, Visit 5 and Visit 6 measured in both groups

Dynamics of EQ5 status score

Time Frame: day 12, day 30, day 60, day 90

Dynamics of EQ5 status score from the start of the study (Visit 1) to Visit 3, Visit 4, Visit 5 and Visit 6 measured in both groups

Secondary Outcomes

  • Dynamics of somatic status(day 12, day 30, day 60, day 90)
  • Dynamics of rehabilitation status(day 12, day 30, day 60, day 90)

Study Sites (1)

Loading locations...

Similar Trials